Diagnostic test allergens used for in vivo diagnosis of allergic diseases are at risk: a European Perspective
Year: 2015
Type: article
Abstract: In the European Union (EU), allergens used for diagnostic tests (TAs) are defined as medicinal products and have to be registered by national authorities. The current situation is not homogeneous. Existing authorizations need to be kept in the market in some EU states, while others need complete new authorizations requiring clinical trials, quality assurance methods, stability studies, and periodic safety update reports. Allergen manufacturers argue that offering a comprehensive panel of TAs may be economically disastrous. Expenses for initiation and maintenance of TA authorizations far exceed their related revenues and manufacturers may be forced to significantly limit their allergen portfolios. The availability of a wide range of high-quality TAs is very important for in vivo diagnoses of IgE-mediated allergies. Increased regulatory demands induce costs that need to be covered by public health organizations or reimbursed by health insurance companies.
Source: Allergy
DOI: 10.1111/all.12676
Institutions: Zentrum für Rhinologie und Allergologie, Aarhus University, European Academy of Allergy and Clinical Immunology, Philipps University of Marburg, Universitätsklinikum Gießen und Marburg, Sorbonne Université, Centre Hospitalier Universitaire de Montpellier, Université Pierre-et-Marie-Curie, Medizinische Hochschule Hannover, Charité – Universitätsmedizin Berlin, University of Padua, Azienda Ospedale - Università Padova, University of Zurich, Vall d'Hebron Hospital Universitari, Fundación de la Sociedad Española de Alergología e Inmunología Clínica, University of Manchester, Royal Manchester Children's Hospital
Language: English
Subfield: Immunology and Allergy
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W1678652856
